Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer.
Radiotherapy (RT)
biliary cancer
cholangiocarcinoma
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
19
1
2021
Statut:
ppublish
Résumé
Although surgical resection is the preferred curative-intent treatment option for patients with non-metastatic, extra-hepatic biliary cancer (EBC), radiotherapy (RT) or chemoradiotherapy (CRT) may be utilized in select cases when surgical resection is not feasible. The purpose of this study is to report the efficacy and adverse events (AEs) associated with CRT for patients with locally advanced and unresectable EBC. This was a retrospective cohort study of patients with EBC, including extra-hepatic cholangiocarcinoma or gallbladder cancer, deemed inoperable who received RT between 1998 and 2018. The median RT dose was 50.4 Gy in 28 fractions and 94% received concurrent 5-fluorouracil. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS) from the start of RT. The cumulative incidence of local progression (LP), locoregional progression (LRP), and distant metastasis (DM) were reported with death as a competing risk. Cox proportional hazards regression models were used to assess for correlation between patient and treatment characteristics and outcomes. Forty-eight patients were included for analysis. The median OS was 12.0 months [95% confidence interval (CI): 2.3-73.2 months]. The 2-, 3-, and 5-year OS were 33% (95% CI: 22-50%), 20% (95% CI: 11-36%), and 7% (95% CI: 2-20%), respectively. The 2-year PFS, LP, LRP, and DM were 21% (95% CI: 12-36%), 27% (95% CI: 17-44%), 31% (95% CI: 20-48%), and 33% (95% CI: 22-50%), respectively. On univariate analysis, biologically effective dose (BED) >59.5 Gy RT is associated with 3- and 5-year survival in a subset of patients with unresectable EBC. Further exploration of the role of RT as part of a multi-modality curative treatment strategy is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Although surgical resection is the preferred curative-intent treatment option for patients with non-metastatic, extra-hepatic biliary cancer (EBC), radiotherapy (RT) or chemoradiotherapy (CRT) may be utilized in select cases when surgical resection is not feasible. The purpose of this study is to report the efficacy and adverse events (AEs) associated with CRT for patients with locally advanced and unresectable EBC.
METHODS
METHODS
This was a retrospective cohort study of patients with EBC, including extra-hepatic cholangiocarcinoma or gallbladder cancer, deemed inoperable who received RT between 1998 and 2018. The median RT dose was 50.4 Gy in 28 fractions and 94% received concurrent 5-fluorouracil. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS) from the start of RT. The cumulative incidence of local progression (LP), locoregional progression (LRP), and distant metastasis (DM) were reported with death as a competing risk. Cox proportional hazards regression models were used to assess for correlation between patient and treatment characteristics and outcomes.
RESULTS
RESULTS
Forty-eight patients were included for analysis. The median OS was 12.0 months [95% confidence interval (CI): 2.3-73.2 months]. The 2-, 3-, and 5-year OS were 33% (95% CI: 22-50%), 20% (95% CI: 11-36%), and 7% (95% CI: 2-20%), respectively. The 2-year PFS, LP, LRP, and DM were 21% (95% CI: 12-36%), 27% (95% CI: 17-44%), 31% (95% CI: 20-48%), and 33% (95% CI: 22-50%), respectively. On univariate analysis, biologically effective dose (BED) >59.5 Gy
CONCLUSIONS
CONCLUSIONS
RT is associated with 3- and 5-year survival in a subset of patients with unresectable EBC. Further exploration of the role of RT as part of a multi-modality curative treatment strategy is warranted.
Identifiants
pubmed: 33457010
doi: 10.21037/jgo-20-245
pii: jgo-11-06-1408
pmc: PMC7807283
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1408-1420Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
2020 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-20-245). KRJ reports that he receives honoraria from RadOncQuestions.com, LLC. The other authors have no conflicts of interest to declare.
Références
BMC Cancer. 2013 Dec 03;13:568
pubmed: 24299517
Strahlenther Onkol. 2004 Dec;180(12):751-7
pubmed: 15592694
J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8
pubmed: 18471707
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Eur J Cancer. 2014 Nov;50(17):2975-82
pubmed: 25241229
Int J Gynecol Cancer. 2013 May;23(4):592-7
pubmed: 23615570
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):357-62
pubmed: 24411609
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):483-8
pubmed: 16242254
Oncotarget. 2019 Jul 08;10(43):4369-4379
pubmed: 31320991
Hepatogastroenterology. 2015 Jan-Feb;62(137):102-7
pubmed: 25911877
Oncol Lett. 2015 Oct;10(4):2537-2542
pubmed: 26622885
Cancer. 2003 Oct 15;98(8):1689-700
pubmed: 14534886
J Clin Oncol. 2015 Aug 20;33(24):2617-22
pubmed: 25964250
Radiat Oncol. 2014 Jan 14;9:26
pubmed: 24422711
J Clin Oncol. 2016 Jan 20;34(3):219-26
pubmed: 26503201
Cancer Chemother Pharmacol. 2016 Oct;78(4):841-6
pubmed: 27586966
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74
pubmed: 12095564
Anticancer Res. 2016 Feb;36(2):737-40
pubmed: 26851032
Arch Surg. 2004 May;139(5):514-23; discussion 523-5
pubmed: 15136352
Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14
pubmed: 22504095
Adv Radiat Oncol. 2019 Aug 21;5(1):77-84
pubmed: 32051893
J Clin Oncol. 2019 Apr 20;37(12):1015-1027
pubmed: 30856044
Anticancer Res. 2019 Jun;39(6):3095-3100
pubmed: 31177154
Radiology. 1995 Jul;196(1):275-80
pubmed: 7784581
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):654-9
pubmed: 20864265
Ann Surg Oncol. 2017 Dec;24(13):4001-4008
pubmed: 29043526
J Clin Oncol. 2016 Feb 10;34(5):460-8
pubmed: 26668346
Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):929-35
pubmed: 9369143
Adv Radiat Oncol. 2016 Oct 29;1(4):237-243
pubmed: 28740893
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1191-8
pubmed: 19201549
Cancer Med. 2018 Oct;7(10):4880-4892
pubmed: 30152073
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):822-9
pubmed: 24969796
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):772-9
pubmed: 17011452
World J Gastroenterol. 2012 May 21;18(19):2364-70
pubmed: 22654427
Eur J Radiol. 2007 May;62(2):175-9
pubmed: 17344008
Radiat Oncol J. 2014 Jun;32(2):63-9
pubmed: 25061574
Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):945-51
pubmed: 8138448
Gut. 1996 Dec;39(6):852-5
pubmed: 9038668
Radiat Oncol. 2018 May 8;13(1):85
pubmed: 29739420
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e143-9
pubmed: 23200173
Strahlenther Onkol. 2002 Dec;178(12):682-7
pubmed: 12491056
J Clin Oncol. 2012 Jun 1;30(16):1934-40
pubmed: 22529261
Radiother Oncol. 2020 Jun;147:111-117
pubmed: 32268230
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1357-65
pubmed: 14630274
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404